Skip to content
Open access

The role of PK/PD modeling and in silico approaches in drug development: A pharmaceutical industry perspective

2026 · Zbornik radova · 0 citations

Abstract

Pharmacokinetic/pharmacodynamic (PK/PD) modeling and in silico approaches have become central to modern drug development, providing a quantitative framework for evidence-based decisions across non-clinical, translational, and clinical stages. Model-informed drug development integrates approaches such as population PK/PD, physiologically based pharmacokinetic and biopharmaceutics modeling (PBPK/PBBM), exposure-response analyses, quantitative systems pharmacology and toxicology, disease progression models, and artificial intelligence/machine learning methods. Population PK/PD modeling is widely applied throughout development. In discovery, these models support candidate selection by defining the degree of target engagement, exposure profile, and dose required for clinical efficacy. They also strengthen toxicology programs by informing study design, improving interpretation of findings, and supporting implementation of the 3Rs principles (replacement, reduction, and refinement). One of the major applications of PBPK is mechanistic absorption modeling, particularly for orally administered drugs. This led to the development of physiologically based biopharmaceutics modeling (PBBM), which integrates gastrointestinal physiology, active pharmaceutical ingredient properties, and formulation characteristics to predict absorption performance and guide formulation development. For pharmaceutical companies, the value of modeling extends beyond operational efficiency to improved evidence generation. Models can integrate fragmented datasets, justify dose and regimen selection, support regulatory labeling, and enable more patient-centered development strategies. Despite challenges such as data quality, model uncertainty, and reliance on assumptions, PK/PD and in silico methods are evolving from supportive analyses into strategic decision-making platforms that accelerate and strengthen drug development.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.